Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin

References

• AgarwalSMcLaughlinTJoyceASynchronizing antihypertensive and lipid-lowering therapies increases patient adherenceJ Clin Hypertens20068Suppl A 5A214P519
   Google Scholar
• ALLHAT investigatorsMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA200228829819712479763
   PubMed Web of Science ®Google Scholar
• AndersonKMCastelliWPLevyDCholesterol and mortality. 30 years of follow-up from the Framingham studyJAMA19872572176803560398
   PubMed Web of Science ®Google Scholar
• AsmarRVolSPannierBHigh blood pressure and associated cardiovascular risk factors in FranceJ Hypertens20011917273211593091
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAMercourisBRTreatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) studyCurr Med Res Opin200218220812201623
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
   PubMed Web of Science ®Google Scholar
• BisognanoJMcLaughlinTRobertsCSIncremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimensAm J Hypertens2004176768315323063
   PubMed Web of Science ®Google Scholar
• BlankRLaSalleJReevesRSingle-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study)J Clin Hypertens2005726473
   PubMedGoogle Scholar
• Blood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336215273514615107
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
   PubMed Web of Science ®Google Scholar
• ChapmanRHBennerJSPetrillaAAPredictors of adherence with antihypertensive and lipid-lowering therapyArch Intern Med200516511475215911728
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 ReportJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet20043646859615325833
   PubMed Web of Science ®Google Scholar
• ConroyRMPyoralaKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• DorvalJFAndersonTBuithieuJReaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart diseaseAm J Cardiol2005952495315642561
   PubMed Web of Science ®Google Scholar
• EUROASPIRE I and II GroupClinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce EventsLancet2001357995100111293642
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study GroupLifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey ProgrammeEur Heart J2001225547211259143
   PubMed Web of Science ®Google Scholar
• FlackJMFerdinandKCNasserSAEpidemiology of hypertension and cardiovascular disease in African AmericansJ Clin Hypertens20035511
   PubMedGoogle Scholar
• FlackJMNovikovSVFerrarioCMBenefits of adherence to anti-hypertensive drug therapyEur Heart J199617Suppl A16208737196
   PubMed Web of Science ®Google Scholar
• FlackJMVictorRWatsonKAmlodipine/atorvastatin single-pill dual therapy improves goal attainment in the treatment of concomitant hypertension and dyslipidemia in African-Americans: the CAPABLE trialJ Clin Hypertens2006a8456
   Google Scholar
• FlackJMVictorRWatsonKAmlodipine/Atorvastatin Single-Pill Dual Therapy Improves 24 Hour Ambulatory Blood Pressure in African-Americans: The CAPABLE TrialJ Clin Hypertens2006b8Suppl A 5A47P-96
   Google Scholar
• GreenlandPKnollMDStamlerJMajor risk factors as antecedents of fatal and nonfatal coronary heart disease eventsJAMA2003290891712928465
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation20041102273915249516
   PubMed Web of Science ®Google Scholar
• Guidelines CommitteeEuropean Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRonnemaaTMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med1998339229349673301
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet19983511755629635947
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• HobbsFDRGensiniGManciniGBJCan combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program)Int J Cardiol20061102425016338012
   PubMed Web of Science ®Google Scholar
• InsullWThe problem of compliance to cholesterol altering therapyJ Intern Med1997241317259159603
   PubMed Web of Science ®Google Scholar
• [IDF] International Diabetes FederationA new worldwide definition of the metabolic syndrome [online]2005 URL:http://http://www.idf.org/home/index.cfm?node=1401
   Google Scholar
• JacksonRLawesCMBennettDATreatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular riskLancet20053654344115680460
   PubMed Web of Science ®Google Scholar
• JukemaJWvan der HoornJWAmlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapyExpert Opin Pharmacother200454596814996641
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KannelWBFifty years of Framingham Study contributions to understanding hypertensionJ Hum Hypertens200014839010723112
   PubMed Web of Science ®Google Scholar
• KhanNAMcAlisterFACampbellNRThe 2004 Canadian recommendations for the management of hypertension: Part II – TherapyCan J Cardiol200420415414968142
   PubMed Web of Science ®Google Scholar
• KhotUNKhotMBBayzerCTPrevalence of conventional risk factors in patients with coronary heart diseaseJAMA200329089890412928466
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ2003326142312829554
   PubMed Web of Science ®Google Scholar
• MacMahonSPetoRCutlerJBlood pressure, stroke, and coronary heart disease. Part 1 Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution biasLancet1990335765741969518
   PubMed Web of Science ®Google Scholar
• MesserliFNeutelJHoustonMMulticenter evaluation of the efficacy and safety of atorvastatin plus amlodipine versus either agent alone in patients with concomitant hypertension and dyslipidemia: the AVALON StudyJ Clin Hypertens2006857181
   Google Scholar
• Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research GroupJAMA19822481465777050440
   PubMed Web of Science ®Google Scholar
• [NCEP] National Cholesterol Education ProgramExecutive Summary of The Third Report of The NCEP Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA200128524869711368702
   PubMed Web of Science ®Google Scholar
• NeatonJDWentworthDSerum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research GroupArch Intern Med199215256641728930
   PubMed Web of Science ®Google Scholar
• NicholMBPatelBVThiebaudPA single pill combining antihypertensive and statin therapies improves patient concordance compared with multi-drug combinations: Results from the Caduet® Concordance Research Program and Education (CARPE) – PBM Concordance StudyJ Clin Hypertens20068456
   Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA200429110718014996776
   PubMed Web of Science ®Google Scholar
• O’MearaJGKardiaSLArmonJJEthnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA studyArch Intern Med20041641313815226165
   PubMed Web of Science ®Google Scholar
• PrestonRAHarveyPHerfertOThe efficacy and safety of fixed-dose combinations of amlodipine and atorvastatin in the treatment of patients with concomitant hypertension and dyslipidemia [abstract]Am J Hypertens200417185A Abstract #P-413
   Web of Science ®Google Scholar
• PrestonRAHarveyPHerfertOReduction in Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidemia with amlodipine/atorvastatinAm J Hypertens2005a18A226
   Web of Science ®Google Scholar
• PearsonTALauroraIChuHThe lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsArch Intern Med20001604596710695686
   PubMed Web of Science ®Google Scholar
• PrestonRASunFTarasenkoLSafety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia in the Respond studyAm J Hypertens2005b18A92A3
   Web of Science ®Google Scholar
• RosalMCOckeneJKLuckmannRCoronary heart disease multiple risk factor reduction Providers’ perspectivesAm J Prev Med200427546015275674
   PubMed Web of Science ®Google Scholar
• SafranDGNeumanPSchoenCPrescription drug coverage and seniors: findings from a 2003 national surveyHealth Aff (Millwood)2005Suppl Web ExclusivesW5-152W5-6615840625
   PubMedGoogle Scholar
• Scandinavian Simvastin Survival GroupRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin Survival Study (4S)Lancet1994344138397968073
   PubMed Web of Science ®Google Scholar
• SchroederKFaheyTEbrahimSHow can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trialsArch Intern Med20041647223215078641
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med1995333130177566020
   PubMed Web of Science ®Google Scholar
• ThomasFBeanKGuizeLCombined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and womenEur Heart J2002235283511922642
   PubMed Web of Science ®Google Scholar
• Tunstall-PedoeHChenRKramarzPPrevalence of individuals with both raised blood pressure and raised cholesterol in WHO MONICA Project population surveys 1989–97Pharmacoepidemiol Drug Saf200413Suppl 1S307S08
   Google Scholar
• TurnbullFEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336215273514615107
   PubMed Web of Science ®Google Scholar
• TurnbullFNealBAlgertCBlood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trialsArch Intern Med20051651410915983291
   PubMed Web of Science ®Google Scholar
• VerschurenWMJacobsDRBloembergBPSerum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries studyJAMA199527413167596000
   PubMed Web of Science ®Google Scholar
• WaldNJLawMRA strategy to reduce cardiovascular disease by more than 80%BMJ2003326141912829553
   PubMed Web of Science ®Google Scholar
• WilliamsBWilsonKLaceyLThe prevalence and management of patients with co-existing hypertension and hypercholesterolaemia in the UKEur Heart J200425abstract suppl5289
   Google Scholar
• WilliamsBPoulterNRBrownMJGuidelines for management of hypertension: report of the fourth working party of the British Hypertension Society 2004-BHS IVJ Hum Hypertens2004181398514973512
   PubMed Web of Science ®Google Scholar
• WilsonPWD’AgostinoRBLevyDPrediction of coronary heart disease using risk factor categoriesCirculation1998971837479603539
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension20044310714638619
   PubMed Web of Science ®Google Scholar
• [WHO] World Health OrganizationIntegrated management of cardiovascular risk. Report of a WHO meeting2002GenevaWHO
   Google Scholar